MA54682A - L-triiodothyronine (t3) destinée à être utilisée pour limiter l'obstruction microvasculaire - Google Patents

L-triiodothyronine (t3) destinée à être utilisée pour limiter l'obstruction microvasculaire

Info

Publication number
MA54682A
MA54682A MA054682A MA54682A MA54682A MA 54682 A MA54682 A MA 54682A MA 054682 A MA054682 A MA 054682A MA 54682 A MA54682 A MA 54682A MA 54682 A MA54682 A MA 54682A
Authority
MA
Morocco
Prior art keywords
triiodothyronine
limit
microvascular obstruction
microvascular
obstruction
Prior art date
Application number
MA054682A
Other languages
English (en)
Other versions
MA54682B1 (fr
Inventor
Iordanis Mourouzis
Constantinos Pantos
Original Assignee
Tseti Ioulia
Uni Pharma Kleon Tsetis Pharmaceutical Laboratories S A
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Tseti Ioulia, Uni Pharma Kleon Tsetis Pharmaceutical Laboratories S A filed Critical Tseti Ioulia
Priority claimed from PCT/EP2019/087056 external-priority patent/WO2020144073A1/fr
Publication of MA54682A publication Critical patent/MA54682A/fr
Publication of MA54682B1 publication Critical patent/MA54682B1/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
    • A61K31/198—Alpha-amino acids, e.g. alanine or edetic acid [EDTA]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner

Landscapes

  • Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Urology & Nephrology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Vascular Medicine (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
MA54682A 2019-01-09 2019-12-27 L-triiodothyronine (t3) pour limitation dans l'obstruction microvasculaire MA54682B1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP19151064 2019-01-09
PCT/EP2019/087056 WO2020144073A1 (fr) 2019-01-09 2019-12-27 L-triiodothyronine (t3) destinée à être utilisée pour limiter l'obstruction microvasculaire

Publications (2)

Publication Number Publication Date
MA54682A true MA54682A (fr) 2021-11-17
MA54682B1 MA54682B1 (fr) 2023-04-28

Family

ID=65010696

Family Applications (1)

Application Number Title Priority Date Filing Date
MA54682A MA54682B1 (fr) 2019-01-09 2019-12-27 L-triiodothyronine (t3) pour limitation dans l'obstruction microvasculaire

Country Status (2)

Country Link
AR (1) AR117776A1 (fr)
MA (1) MA54682B1 (fr)

Also Published As

Publication number Publication date
AR117776A1 (es) 2021-08-25
MA54682B1 (fr) 2023-04-28

Similar Documents

Publication Publication Date Title
MA52486A (fr) Pyridazinones utilisés en tant qu'inhibiteurs de parp7
MA52942A (fr) Composés inhibiteurs d'oga
MA52004A (fr) Inhibiteurs d'o-glycoprotéine-2-acétamido-2-désoxy-3-d-glycopyranosidase
MA52939A (fr) Composés inhibiteurs d'oga
MA46652A (fr) Polythérapie pour l'inhibition de c3
MA45688A (fr) Compositions et procédés de potentialisation d'agents antimicrobiens
MA49253A (fr) Compositions solides pour administration orale
MA54052A (fr) Formulation d'anticorps
FR3022462B1 (fr) Composition orale d'anticorps anti-tnfalpha
MA53875A (fr) Traitement avec des compositions d'igg hautement sialylées
MA53391A (fr) Compositions pour l'agriculture et procédés associés
DK3979827T3 (da) Næringssammensætning omfattende 2'fucosyllactose og 3'galactosyllactose
MA55507A (fr) Macitentan destiné à être utilisé dans le traitement de l'hypertension portopulmonaire
MA54682A (fr) L-triiodothyronine (t3) destinée à être utilisée pour limiter l'obstruction microvasculaire
MA47106A (fr) Formulations d'anticorps anti-tnf alpha
MA54571A (fr) Dispositif d'injection
MA54070A (fr) Variants fc5 humanisés et stabilisés pour l'amélioration du transport à travers la barrière hémato-encéphalique
MA52937A (fr) Composés inhibiteurs d'oga
MA52936A (fr) Composés inhibiteurs d'oga
MA54692A (fr) Composition pour l'agriculture anti-pathogènes liquide
MA55809A (fr) Formulation d'anticorps anti-il-6
MA52148A (fr) Peptides chimères pour administration d'antisens
MA52938A (fr) Composés inhibiteurs d'oga
FR3005411B1 (fr) Association d'actifs pour une administration par voie orale pour ameliorer la qualite des ongles.
MA54570A (fr) Dispositif d'injection